REGEN-COV™(Casirivimab和Imdevimab)联合Molnupiravir InStage- V CKD患者合并症状性COVID-19肺炎1例报告

M. Mostafi, Ahammad Shamir Shawrov, Mohammad Abdul Wahab, A. Saleh
{"title":"REGEN-COV™(Casirivimab和Imdevimab)联合Molnupiravir InStage- V CKD患者合并症状性COVID-19肺炎1例报告","authors":"M. Mostafi, Ahammad Shamir Shawrov, Mohammad Abdul Wahab, A. Saleh","doi":"10.47363/jone/2022(2)105","DOIUrl":null,"url":null,"abstract":"Combination of two human monoclonal antibodies, Casirivimab and imdevimab, commonly termed as Cocktail therapy recommended for the treatment and prevention of COVID-19. It is administered as an infusion or subcutaneous injection. Molnupiravir is an antiviral medication that inhibits the replication of certain RNA viruses. There is very limited data available regarding co administration of oral Molnupiravir along with intravenous REGEN-COV™ (Casirivimab and imdevimab) in CKD patient. Here, we report the successful outcome of REGEN-COV™ along with oral Molnupiravir in a CKD Stage V hospitalized patient with Symptomatic COVID-19 Pneumonia","PeriodicalId":415214,"journal":{"name":"Journal of Nephrology & Endocrinology Research","volume":"101 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"REGEN-COV™ (Casirivimab and Imdevimab) along with Molnupiravir InStage- V CKD Patient with Symptomatic COVID-19 Pneumonia: A Case Report\",\"authors\":\"M. Mostafi, Ahammad Shamir Shawrov, Mohammad Abdul Wahab, A. Saleh\",\"doi\":\"10.47363/jone/2022(2)105\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Combination of two human monoclonal antibodies, Casirivimab and imdevimab, commonly termed as Cocktail therapy recommended for the treatment and prevention of COVID-19. It is administered as an infusion or subcutaneous injection. Molnupiravir is an antiviral medication that inhibits the replication of certain RNA viruses. There is very limited data available regarding co administration of oral Molnupiravir along with intravenous REGEN-COV™ (Casirivimab and imdevimab) in CKD patient. Here, we report the successful outcome of REGEN-COV™ along with oral Molnupiravir in a CKD Stage V hospitalized patient with Symptomatic COVID-19 Pneumonia\",\"PeriodicalId\":415214,\"journal\":{\"name\":\"Journal of Nephrology & Endocrinology Research\",\"volume\":\"101 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Nephrology & Endocrinology Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47363/jone/2022(2)105\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nephrology & Endocrinology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47363/jone/2022(2)105","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

两种人单克隆抗体卡西里维单抗和伊德维单抗的联合,通常被称为鸡尾酒疗法,推荐用于治疗和预防COVID-19。它以输注或皮下注射的方式施用。Molnupiravir是一种抗病毒药物,可以抑制某些RNA病毒的复制。关于CKD患者口服Molnupiravir与静脉注射regencov™(Casirivimab和imdevimab)联合给药的数据非常有限。在这里,我们报告了REGEN-COV™联合口服莫诺匹拉韦治疗CKD V期住院患者症状性COVID-19肺炎的成功结果
本文章由计算机程序翻译,如有差异,请以英文原文为准。
REGEN-COV™ (Casirivimab and Imdevimab) along with Molnupiravir InStage- V CKD Patient with Symptomatic COVID-19 Pneumonia: A Case Report
Combination of two human monoclonal antibodies, Casirivimab and imdevimab, commonly termed as Cocktail therapy recommended for the treatment and prevention of COVID-19. It is administered as an infusion or subcutaneous injection. Molnupiravir is an antiviral medication that inhibits the replication of certain RNA viruses. There is very limited data available regarding co administration of oral Molnupiravir along with intravenous REGEN-COV™ (Casirivimab and imdevimab) in CKD patient. Here, we report the successful outcome of REGEN-COV™ along with oral Molnupiravir in a CKD Stage V hospitalized patient with Symptomatic COVID-19 Pneumonia
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信